Effects of rivastigmine on common symptomatology of Alzheimer’s disease (EXPLORE)

Author： Gauthier Serge Juby Angela Dalziel William Réhel Bonita Schecter Robyn

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.26, Iss.5, 2010-05, pp. : 1149-1160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Reduced Release of GH by GHRH in 8 Subjects Aged 65–69 Years Is Augmented Considerably by Rivastigmine, a Drug for Alzheimer’s Disease

Gerontology, Vol. 49, Iss. 3, 2003-04 ,pp. : 191-195

Karger

Access to resources Recommend Favorite

Pain and Alzheimer’s Disease

Gerontology, Vol. 46, Iss. 5, 2000-08 ,pp. : 235-241

Karger

Access to resources Recommend Favorite

Somatotype in Alzheimer’s Disease

Gerontology, Vol. 53, Iss. 4, 2007-03 ,pp. : 200-204

Karger

Access to resources Recommend Favorite

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

By Farlow Martin R. Alva Gus Meng Xiangyi Olin Jason T.

Current Medical Research and Opinion, Vol. 26, Iss. 2, 2010-02 ,pp. : 263-269

Informa Healthcare

Access to resources Recommend Favorite

News & Views in ... Alzheimer''s Disease

Therapy, Vol. 8, Iss. 5, 2011-09 ,pp. : 467-470

Future Medicine

Access to resources Recommend Favorite